These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7003804)

  • 1. Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bay g 6575.
    Carreras LO; Chamone DA; Klerckx P; Vermylen J
    Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):663-70. PubMed ID: 7003804
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased release of vascular prostacyclin-like activity after long-term treatment of diabetic rats with Bay g 6575.
    Chamone DA; van Damme B; Carreras LO; Vermylen J
    Haemostasis; 1981; 10(6):297-303. PubMed ID: 7035306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nafazatrom (BAY g 6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall.
    Klitzke AK
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):220-8. PubMed ID: 6391401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase.
    Wong PY; Chao PH; McGiff JC
    J Pharmacol Exp Ther; 1982 Dec; 223(3):757-60. PubMed ID: 6754908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
    Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE
    Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular prostacyclin release and metabolic derangement in diabetes.
    Harrison HE; Johnson M
    Horm Metab Res Suppl; 1981; 11():43-9. PubMed ID: 7033096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
    Coker SJ; Parratt JR
    J Mol Cell Cardiol; 1984 Jan; 16(1):43-52. PubMed ID: 6366241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound.
    Vermylen J; Chamone DA; Verstraete M
    Lancet; 1979 Mar; 1(8115):518-20. PubMed ID: 85106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.
    Shepherd GL; Lewis PJ; Blair IA; de Mey C; MacDermot J
    Br J Clin Pharmacol; 1983 Jan; 15(1):77-81. PubMed ID: 6342639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.
    Massad L; Plotkine M; Boulu RG
    Thromb Res; 1988 Jun; 50(5):617-25. PubMed ID: 3137682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of arterial thrombosis and platelet function by nafazatrom.
    Buchanan MR; Blajchman M; Hirsh J
    Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of insulin treatment on prostacyclin in experimental diabetes.
    Harrison HE; Reece AH; Johnson M
    Diabetologia; 1980 Jan; 18(1):65-8. PubMed ID: 6988267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential changes of adrenoceptor- and muscarinic receptor-linked prostacyclin synthesis by the aorta and urinary bladder of the diabetic rat.
    Jeremy JY; Thompson CS; Mikhailidis DP
    Br J Pharmacol; 1993 Apr; 108(4):1131-6. PubMed ID: 8485622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of experimentally induced diabetes on swine vascular prostacyclin (PGI2) synthesis.
    Silberbauer K; Clopath P; Sinzinger H; Schernthaner G
    Artery; 1980; 8(1):30-6. PubMed ID: 6448594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes.
    Wang LN; Tang Z; Shou I; Fukui M; Tomino Y
    Nephron; 1996; 73(4):637-43. PubMed ID: 8856263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma prostaglandin levels in rats with diabetes mellitus and diabetic ketoacidosis.
    Axelrod L; Levine L
    Diabetes; 1982 Nov; 31(11):994-1001. PubMed ID: 6816644
    [No Abstract]   [Full Text] [Related]  

  • 17. Recirculation of prostacyclin (PGI2) in the dog.
    Dusting GJ; Moncada S; Vane JR
    Br J Pharmacol; 1978 Oct; 64(2):315-20. PubMed ID: 361136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiaggregatory efficacy and its time-course after application of acetylsalicylic acid, prostacyclin and nafazatrom in vivo.
    Herrmann KS
    Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):150-8. PubMed ID: 6393886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostacyclin and pathogenesis of hemodynamic abnormalities of diabetic ketoacidosis in rats.
    Quyyumi AA; Iaffaldano R; Guerrero JL; Ryan CA; Powell WJ; Axelrod L
    Diabetes; 1989 Dec; 38(12):1585-94. PubMed ID: 2511053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of cortex moutan on PGI2, TXA2, ET and NO in diabetic rats].
    Min CY; Liu HQ; Zhan F; Qiu WZ
    Zhong Yao Cai; 2007 Jun; 30(6):687-90. PubMed ID: 17918442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.